HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HU-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HU-6 is under development for the treatment of non-alcoholic steatohepatitis (NASH), non alcoholic fatty liver disease (NAFLD), type 2 diabetes, severe hypertriglyceridemia (SHTG) and heart failure with preserved ejection fraction (HFpEF). It is administered through oral route.
Rivus Pharmaceuticals overview
Rivus Pharmaceuticals is a developer of controlled metabolic accelerators that providing patients with oral small molecule therapeutics which address the underlying metabolic risk factors. The company is headquartered in Charlottesville, Virginia, the US.
For a complete picture of HU-6’s drug-specific PTSR and LoA scores, buy the report here.